These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20662899)

  • 21. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
    Rajala HLM; Missiry ME; Ruusila A; Koskenvesa P; Brümmendorf TH; Gjertsen BT; Janssen J; Lotfi K; Markevärn B; Olsson-Strömberg U; Stenke L; Stentoft J; Richter J; Hjorth-Hansen H; Kreutzman A; Mustjoki S
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1543-1554. PubMed ID: 28337541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
    Rossignol A; Levescot A; Jacomet F; Robin A; Basbous S; Giraud C; Roy L; Guilhot F; Turhan AG; Barra A; Herbelin A; Gombert JM
    Eur J Immunol; 2012 Jul; 42(7):1870-5. PubMed ID: 22585600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
    Reinhold U; Hennig E; Leiblein S; Niederwieser D; Deininger MW
    Leukemia; 2003 Oct; 17(10):1925-9. PubMed ID: 14513039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
    Aswald JM; Lipton JH; Aswald S; Messner HA
    Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
    Yeh CH; Abdool A; Bruey JM
    Cancer Biomark; 2010; 7(6):295-303. PubMed ID: 21694468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
    Sillaber C; Herrmann H; Bennett K; Rix U; Baumgartner C; Böhm A; Herndlhofer S; Tschachler E; Superti-Furga G; Jäger U; Valent P
    Eur J Clin Invest; 2009 Dec; 39(12):1098-109. PubMed ID: 19744184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
    de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
    Blood; 2013 Jul; 122(2):227-38. PubMed ID: 23719297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of centrosome aberrations in disease-unrelated cells from patients with tumor treated with tyrosine kinase inhibitors.
    Giehl M; Leitner A; Haferlach C; Duesberg P; Hofmann WK; Hofheinz R; Seifarth W; Hochhaus A; Fabarius A
    Eur J Haematol; 2010 Aug; 85(2):139-48. PubMed ID: 20408871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML.
    Brück O; Blom S; Dufva O; Turkki R; Chheda H; Ribeiro A; Kovanen P; Aittokallio T; Koskenvesa P; Kallioniemi O; Porkka K; Pellinen T; Mustjoki S
    Leukemia; 2018 Jul; 32(7):1643-1656. PubMed ID: 29925907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Blake S; Hughes TP; Mayrhofer G; Lyons AB
    Clin Immunol; 2008 Jun; 127(3):330-9. PubMed ID: 18395492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
    Front Immunol; 2019; 10():2493. PubMed ID: 31695700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
    Christiansson L; Söderlund S; Mangsbo S; Hjorth-Hansen H; Höglund M; Markevärn B; Richter J; Stenke L; Mustjoki S; Loskog A; Olsson-Strömberg U
    Mol Cancer Ther; 2015 May; 14(5):1181-91. PubMed ID: 25761894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.